»ý¹°ÇÐÀ¸·Î µ¹¾Æ°¡±â : ¸é¿ªÄ¡·á¿¡¼ Á¤µµ¿Í Áøº¸ÀÇ À¶ÇÕ
- Combining multispecifics with cellular modalities
´ÙÁ߯¯À̼º°ú ¼¼Æ÷ ¸ð´Þ¸®Æ¼¸¦ Á¶ÇÕ - ML and data in bi/multispecific development
ÀÌÁ߯¯À̼º/´ÙÁ߯¯À̼º °³¹ß¿¡¼ÀÇ ML°ú µ¥ÀÌÅÍ - Addressing safety and regulatory hurdles
¾ÈÀü¼º°ú ±ÔÁ¦»ó Àå¾Ö¹°¿¡ ´ëÇÑ ´ëó - Learnings from solid tumor clinical successes
°íÇü¾Ï ÀÓ»óÀû ¼º°ú·ÎºÎÅÍ ¾òÀº ±³ÈÆ
- Improvements in linker technologies
¸µÄ¿ ±â¼úÀÇ Çâ»ó - Site-specific conjugation
ºÎÀ§ ƯÀÌÀû ÄÁÁê°ÔÀÌ¼Ç - Addressing resistance and toxicity to improve therapeutic indexes
Ä¡·á ÁöÇ¥ÀÇ °³¼±À» ÇâÇÑ ³»¼º°ú µ¶¼º¿¡ ´ëÇÑ ´ëó - Enhancing solid tumor targeting and specificity for better efficacy
°íÇü¾Ï Ÿ°ÙÆÃ°ú ƯÀ̼ºÀ» °È, À¯È¿¼ºÀÇ Çâ»ó